Prophylaxis and treatment of anthrax in pregnant women

Obstetrics and Gynecology

Volumn 122, Issue 4, 2013, Pages 885-900

  Meaney Delman, Dana ^a,b   Rasmussen, Sonja A ^a,b   Beigi, Richard H ^a,b   Zotti, Marianne E ^a,b   Hutchings, Yalonda ^a,b   Bower, William A ^a,b   Treadwell, Tracee A ^a,b   Jamieson, Denise J ^a,b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DORIPENEM; DOXYCYCLINE; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; HUMAN; INFECTION PREVENTION; MEDLINE; MORBIDITY; MORTALITY; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; ANTHRAX; ANTI-INFECTIVE AGENTS; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84889841352     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3182a5fdfd     Document Type: Review

References (150)

1. Shepard CW, Soriano-Gabarro M, Zell ER, Hayslett J, Lukacs S, Goldstein S, et al. Antimicrobial postexposure prophylaxis for anthrax: Adverse events and adherence. Emerg Infect Dis 2002;8:1124-32.
2. Centers for Disease Control and Prevention (CDC). Update: interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep 2001;50: 1014-6.
3. Management of asymptomatic pregnant or lactating women exposed to anthrax. ACOG Committee on Obstetric Practice. ACOG Committee Opinion number 268, February 2002. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002;99:366-8.
4. Lutter R. Letter by Randall Lutter, Deputy Commissioner for Policy, February 25, 2008. Available at: http://www.fda.gov/downloads/Drugs/ EmergencyPreparedness/Bioterrorismand-DrugPreparedness/UCM107309.pdf. Retrieved February 9, 2012.
5. Prepositioning antibiotics for anthrax. Washington, DC: Institute of Medicine; 2011.
6. Department of Health and Human Services. Renewal of declaration regarding emergency use of doxycycline hyclate tablets. Washington, DC: Federal Register; 2011.
7. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002;287:2236-52.
8. Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. Systematic review: A century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006; 144:270-80.
9. Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, et al. Investigation of bioterrorismrelated anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002;8:1019-28.
10. Meaney-Delman D, Zotti ME, Rasmussen SA, Strasser S, Shadomy S, Turcios-Ruiz RM, et al. Anthrax cases in pregnant and postpartum women: A systematic review. Obstet Gynecol 2012;120:1439-49.
11. Wright JG, Quinn CP, Shadomy S, Messonnier N. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010;59:1-30.
12. Gough AW, Kasali OB, Sigler RE, Baragi V. Quinolone arthropathy-acute toxicity to immature articular cartilage. Toxicol Pathol 1992;20:436-49.
13. Ciprofloxacin REPROTEXT- Document (Version 5.1) [Intranet]. Available at: http://www.reprotox.org/Default.aspx. Retrieved December 2012.
14. Doxycycline REPROTEXT- Document (Version 5.1) [Intranet]. Available at: http://www.reprotox.org/Default.aspx. Retrieved December 2012.
15. Cohlan S, Bevelander G, Tiamsic T. Growth inhibition of prematures receiving tetracycline. Am J Dis Child 1963; 105:45.
16. Kutscher AH, Zegarelli EV, Tovell HM, Hochberg B, Hauptman J. Discoloration of deciduous teeth induced by administration of tetracycline antepartum. Am J Obstet Gynecol 1966;96:291-2.
17. Stern EJ, Uhde KB, Shadomy SV, Messonnier N. Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis 2008;14. pii:07-0969. DOI: 10.3201/eid1404.070969.
18. Rifampin REPROTEXT- Document (Version 5.1) [Intranet]. Available at: http://www.reprotox.org/Default.aspx. Retrieved December 2012.
19. Chloramphenicol REPROTEXT- Document (Version 5.1) [Intranet]. Available at: http://www.reprotox.org/Default.aspx. Retrieved December 2012.
20. Krasinski K, Perkin R, Rutledge J. Gray baby syndrome revisited. Clin Pediatr (Phila) 1982;21:571-2.
21. Andrew MA, Easterling TR, Carr DB, Shen D, Buchanan ML, Rutherford T, et al. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther 2007;81:547-56.
22. Philipson A. Pharmacokinetics of ampicillin during pregnancy. J Infect Dis 1977;136:370-6.
23. Philipson A. Plasma levels of ampicillin in pregnant women following administration of ampicillin and pivampicillin. Am J Obstet Gynecol 1978;130:674-83.
24. Zajicek A, Giacoia GP. Obstetric clinical pharmacology: coming of age. Clin Pharmacol Ther 2007;81:481-2.
25. Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol 2006;107:1120-38.
26. Bar-Oz B, Moretti ME, Boskovic R, O'Brien L, Koren G. The safety of quinolones- A meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2009;143:75-8.
27. Briggs GG, Freeman AE, Yaffe SJ. Drugs in pregnancy and lactation. 6th edition. Baltimore (MD): Lippincott Williams & Wilkins; 2001.
28. Berkovitch M, Pastuszak A, Gazarian M, Lewis M, Koren G. Safety of the new quinolones in pregnancy. Obstet Gynecol 1994;84:535-8.
29. Bomford J, Ledger J, O'Keefe B, Reiter C. Ciprofloxacin use during pregnancy. Drugs 1993;45:461-2.
30. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer SM, Gideon PS, et al. Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatr Perinat Epidemiol 2009;23:18-28.
31. Eric M, Sabo A. Teratogenicity of antibacterial agents. Coll Antropol 2008;32:919-25.
32. Koul PA, Wani JI, Wahid A. Ciprofloxacin for multiresistant enteric fever in pregnancy. Lancet 1995;346:307-8.
33. Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld AE, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: A multicenter prospective controlled study. Antimicrob Agents Chemother 1998;42: 1336-9.
34. Schaefer C, Amoura-Elefant E, Vial T, Ornoy A, Garbis H, Robert E, et al. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol 1996;69:83-9.
35. Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998;105:882-9.
36. Wogelius P, Norgaard M, Gislum M, Pedersen L, Schonheyder HC, Sorensen HT. Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones. Int J Antimicrob Agents 2005;26:323-6.
37. Leppig KA, Werler MM, Cann CI, Cook CA, Holmes LB. Predictive value of minor anomalies. I. Association with major malformations. J Pediatr 1987;110:531-7.
38. Larsen H, Nielsen GL, Schonheyder HC, Olesen C, Sorensen HT. Birth outcome following maternal use of fluoroquinolones. Int J Antimicrob Agents 2001;18:259-62.
39. Giamarellou H, Kolokythas E, Petrikkos G, Gazis J, Aravantinos D, Sfikakis P. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med 1989; 87:49S-51S.
40. Polachek H, Holcberg G, Sapir G, Tsadkin-Tamir M, Polachek J, Katz M, et al. Transfer of ciprofloxacin, ofloxacin and levofloxacin across the perfused human placenta in vitro. Eur J Obstet Gynecol Reprod Biol 2005;122:61-5.
41. Ozyuncu O, Beksac MS, Nemutlu E, Katlan D, Kir S. Maternal blood and amniotic fluid levels of moxifloxacin, levofloxacin and cefixime. J Obstet Gynaecol Res 2010;36: 484-7.
42. Ozyuncu O, Nemutku E, Katlan D, Kir S, Beksac M. Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone. Int J Antimicrob Agents 2010;36:175-8.
43. Nemutlu E, Kir S, Eroglu H, Katlan D, Ozek A, Ozyuncu O, et al. Comparison of pharmacokinetic profiles of moxifloxacin in Caesarean versus non-pregnant sectioned women by fully validated HPLC with fluorescence detection. Comb Chem High Throughput Screen 2010;13:502-9.
44. Czeizel AE, Rockenbauer M. Teratogenic study of doxycycline. Obstet Gynecol 1997;89:524-8.
45. Horne HW Jr, Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies: A prospective study. Int J Fertil 1980;25:315-7.
46. Kazy Z, Puhó EH, Czeizel AE. Effect of doxycycline treatment during pregnancy for birth outcomes. Reprod Toxicol 2007; 24:279-80.
47. Molgaard-Nielsen D, Hviid A. Maternal use of antibiotics and the risk of orofacial clefts: A nationwide cohort study. Pharmacoepidemiol Drug Saf 2012;21:246-53.
48. Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med 2009;163:978-85.
49. Reeves MF, Lohr PA, Hayes JL, Harwood BJ, Creinin MD. Doxycycline serum levels at the time of dilation and evacuation with two dosing regimens. Contraception 2009;79: 129-33.
50. McCormack WM, Rosner B, Lee YH, Munoz A, Charles D, Kass EH. Effect on birth weight of erythromycin treatment of pregnant women. Obstet Gynecol 1987;69:202-7.
51. Phillipson A, Sabath L, Charles D. Erythromycin and clindamycin absorption and elimination in pregnant women. Clin Pharmacol Ther 1975;19:68-77.
52. DeHaan RM, Metzler CM, Schellenberg D, Vandenbosch WD. Pharmacokinetic studies of clindamycin phosphate. J Clin Pharmacol 1973;13:190-209.
53. Muller AE, Mouton JW, Oostvogel PM, Dörr PJ, Voskuyl RA, DeJongh J, et al. Pharmacokinetics of clindamycin in pregnant women in the peripartum period. Antimicrob Agents Chemother 2010;54:2175-81.
54. Gilstrap LC 3rd, Bawdon RE, Burris J. Antibiotic concentration in maternal blood, cord blood, and placental membranes in chorioamnionitis. Obstet Gynecol 1988;72:124-5.
55. Philipson A, Sabath LD, Charles D. Transplacental passage of erythromycin and clindamycin. N Engl J Med 1973;288: 1219-21.
56. Weinstein AJ, Gibbs RS, Gallagher M. Placental transfer of clindamycin and gentamicin in term pregnancy. Am J Obstet Gynecol 1976;124:688-91.
57. Berkovitch M, Diav-Citrin O, Greenberg R, Cohen M, Bulkowstein M, Shechtman S, et al. First-trimester exposure to amoxycillin/clavulanic acid: A prospective, controlled study. Br J Clin Pharmacol 2004;58:298-302.
58. CaveneeMR, Farris JR, Spalding TR, Barnes DL, Castaneda YS, Wendel GD Jr. Treatment of gonorrhea in pregnancy. Obstet Gynecol 1993;81:33-8.
59. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: A population-based case-control teratologic study. Eur J Obstet Gynecol Reprod Biol 2001; 97:188-92.
60. Eric M, Leppee M, Sabo A, Culig J. Beta-lactam antibiotics during pregnancy: A cross-sectional comparative study Zagreb-Novi Sad. Eur Rev Med Pharmacol Sci 2012;16: 103-10.
61. Jepsen P, Skriver MV, Floyd A, Lipworth L, Schonheyder HC, Sorensen HT. A population-based study of maternal use of amoxicillin and pregnancy outcome in Denmark. Br J Clin Pharmacol 2003;55:216-21.
62. Lin KJ, Mitchell AA, Yau WP, Louik C, Hernandez-Diaz S. Maternal exposure to amoxicillin and the risk of oral clefts. Epidemiology 2012;23:699-705.
63. Ou MC, Pang CC, Chen FM, Su CH, Ou D. Antibiotic treatment for threatened abortion during the early first trimester in women with previous spontaneous abortion. Acta Obstet Gynecol Scand 2001;80:753-6.
64. Pedler SJ, Bint AJ. Comparative study of amoxicillin-clavulanic acid and cephalexin in the treatment of bacteriuria during pregnancy. Antimicrob Agents Chemother 1985;27:508-10.
65. Puhó EH, Szunyogh M, Métneki J, Czeizel AE. Drug treatment during pregnancy and isolated orofacial clefts in Hungary. Cleft Palate Craniofac J 2007;44:194-202.
66. Rahangdale L, Guerry S, Bauer HM, Packel L, Rhew M, Baxter R, et al. An observational cohort study of Chlamydia trachomatis treatment in pregnancy. Sex Transm Dis 2006;33: 106-10.
67. Shaw GM, Todoroff K, Velie EM, Lammer EJ. Maternal illness, including fever and medication use as risk factors for neural tube defects. Teratology 1998;57:1-7.
68. Buckingham M, Welply G, Miller JF, Elstein M. Gastro-intestinal absorption and transplacental transfer of amoxycillin during labour and the influence of metoclopramide. Curr Med Res Opin 1975;3:392-6.
69. Muller AE, DeJongh J, Oostvogel PM, Voskuyl RA, Dorr PJ, Danhof M, et al. Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes. Am J Obstet Gynecol 2008;198:108.e1-6.
70. Muller AE, Oostvogel PM, DeJongh J, Mouton JW, Steegers EA, Dorr PJ, et al. Pharmacokinetics of amoxicillin in maternal, umbilical cord, and neonatal sera. Antimicrob Agents Chemother 2009;53:1574-80.
71. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population- based case-control teratologic study of oral chloramphenicol treatment during pregnancy. Eur J Epidemiol 2000; 16:323-7.
72. Wendel GD Jr, Stark BJ, Jamison RB, Molina RD, Sullivan TJ. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 1985;312:1229-32.
73. Jick H, Holmes LB, Hunter JR, Madsen S, Stergachis A. Firsttrimester drug use and congenital disorders. JAMA 1981;246: 343-6.
74. Kullander S, Källén B. A prospective study of drugs and pregnancy. I. Psychopharmaca. Acta Obstet Gynecol Scand 1976; 55:25-33.
75. Saxen I. Associations between oral clefts and drugs taken during pregnancy. Int J Epidemiol 1975;4:37-44.
76. Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT. Oral phenoxymethylpenicillin treatment during pregnancy. Results of a population-based Hungarian case-control study. Arch Gynecol Obstet 2000;263:178-81.
77. Johnson JR, Colombo DF, Gardner D, Cho E, Fan-Havard P, Shellhaas CS. Optimal dosing of penicillin G in the third trimester of pregnancy for prophylaxis against group B Streptococcus. Am J Obstet Gynecol 2001;185:850-3.
78. Wasz-Höckert O, Nummi S, Vuopala S, Järvinen PA. Transplacental passage of azidocillin, ampicillin and penicillin G during early and late pregnancy. Scand J Infect Dis 1970;2: 125-30.
79. Woltz JH, Wiley MM. The transmission of penicillin to the previable fetus; its significance in prenatal syphilis. J Am Med Assoc 1946;131:969.
80. Weeks JW, Myers SR, Lasher L, Goldsmith J, Watkins C, Gall SA. Persistence of penicillin G benzathine in pregnant group B streptococcus carriers. Obstet Gynecol 1997;90: 240-3.
81. Hutter A, Parks J. The transmission of penicillin through the placenta. A preliminary report. J Obstet Gynecol 1945;49: 663-5.
82. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 2011;17:958-63.
83. Woltz J, Zintel Z. The transmission of penicillin to amniotic fluid and fetal blood in the human. Am J Obstet Gynecol 1945;50:338-40.
84. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population- based case-control teratologic study of ampicillin treatment during pregnancy. Am J Obstet Gynecol 2001;185: 140-7.
85. Aselton P, Jick H, Milunsky A, Hunter JR, Stergachis A. Firsttrimester drug use and congenital disorders. Obstet Gynecol 1985;65:451-5.
86. Rothman KF, Pochi PE. Use of oral and topical agents for acne in pregnancy. J Am Acad Dermatol 1988;19:431-42.
87. Czeizel AE, Puho EH, Acs N, Banhidy F. Use of specified critical periods of different congenital abnormalities instead of the first trimester concept. Birth Defects Res A Clin Mol Teratol 2008;82:139-46.
88. Colley DK, Kay J, Gibson G. Amoxycillin and ampicillin: A study of their use in pregnancy. Aust J Pharm 1983;107-11.
89. Zierler S, Rothman KJ. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med 1985;313:347-52.
90. Chamberlain A, White S, Bawdon R, Thomas S, Larsen B. Pharmacokinetics of ampicillin and sulbactam in pregnancy. Am J Obstet Gynecol 1993;168:667-73.
91. Kubacka RT, Johnstone HE, Tan HS, Reeme PD, Myre SA. Intravenous ampicillin pharmacokinetics in the third trimester of pregnancy. Ther Drug Monit 1983;5:55-60.
92. Philipson A. Persistance of ampicillin in the intrauterine content following single and multiple doses to pregnant women. Acta Obstet Gynecol Scand 1981;60:121-3.
93. Jordheim O, Hagen AG. Study of ampicillin levels in maternal serum, umbilical cord serum and amniotic fluid following administration of pivampicillin. Acta Obstet Gynecol Scand 1980;59:315-7.
94. Bloom SL, Cox SM, Bawdon RE, Gilstrap LC. Ampicillin for neonatal group B streptococcal prophylaxis: how rapidly can bactericidal concentrations be achieved? Am J Obstet Gynecol 1996;175:974-6.
95. Adamkin DH, Marshall E, Weiner LB. The placental transfer of ampicillin. Am J Perinatol 1984;1:310-1.
96. Creatsas G, Pavlatos M, Lolis D, Kaskarelis D. Ampicillin and gemtamicin in the treatment of fetal intrauterine infections. J Perinat Med 1980;8:13-8.
97. Kraybill EN, Chaney NE, McCarthy LR. Transplacental ampicillin: inhibitory concentrations in neonatal serum. Am J Obstet Gynecol 1980;138:793-6.
98. Yow MD, Mason EO, Leeds LJ, Thompson PK, Clark DJ, Gardner SE. Ampicillin prevents intrapartum transmission of group B streptococcus. JAMA 1979;241:1245-7.
99. Bray RE, Boe RW, Johnson WL. Transfer of ampicillin into fetus and amniotic fluid from maternal plasma in late pregnancy. Am J Obstet Gynecol 1966;96:938-42.
100. MacAulay MA, Abou-Sabe M, Charles D. Placental transfer of ampicillin. Am J Obstet Gynecol 1966;96:943-50.
101. Colombo DF, Lew JL, Pedersen CA, Johnson JR, Fan- Havard P. Optimal timing of ampicillin administration to pregnant women for establishing bactericidal levels in the prophylaxis of Group B Streptococcus. Am J Obstet Gynecol 2006;194:466-70.
102. Hirsch HA, Dreher E, Perrochet A, Schmid E. Transfer of ampicillin to the fetus and amniotic fluid during continuous infusion (steady state) and by repeated single intravenous injections to the mother. Infection 1974;2:207-12.
103. Stewart KS, Shafi M, Andrews J, Williams JD. Distribution of parenteral ampicillin and cephalosporins in late pregnancy. J Obstet Gynaecol Br Commonw 1973;80:902-8.
104. Biró L, Iván E, Elek E, Arr M. Data on the tissue concentration of antibiotics in man tissue concentrations of semi-synthetic penicillins in the fetus. Int Z Klin Pharmakol Ther Toxikol 1970;4:321-4.
105. Fisher AM, Smith MR. The prophylactic use of ampicillin and its trans-placental passage after amniotomy. J Obstet Gynaecol Br Commonw 1967;74:855-61.
106. Maberry MC, Trimmer KJ, Bawdon RE, Sobhi S, Dax JB, Gilstrap LC 3rd. Antibiotic concentration in maternal blood, cord blood and placental tissue in women with chorioamnionitis. Gynecol Obstet Invest 1992;33:185-6.
107. Elek E, Ivãn E, Arr M. Passage of penicillins from mother to foetus in humans. Int J Clin Pharmacol 1972;6:223-8.
108. Blecher TE, Edgar WM, Melville HA, Peel KR. Transplacental passage of ampicillin. Br Med J 1966;1:137-9.
109. Bolognese RJ. Ampicillin: Transfer into fetus and amniotic fluid. Rocky Mt Med J 1968;65:72-4.
110. Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide- Tetanus toxoid conjugate vaccine. Vaccine 2003;21: 3468-72.
111. Hnat M, Bawdon RE. Transfer of meropenem in the ex vivo human placenta perfusion model. Infect Dis Obstet Gynecol 2005;13:223-7.
112. Roushan MR, Baiani M, Asnafi N, Saedi F. Outcomes of 19 pregnant women with brucellosis in Babol, northern Iran. Trans R Soc Trop Med Hyg 2011;105:540-2.
113. Gulsun S, Aslan S, Satici O, Gul T. Brucellosis in pregnancy. Trop Doct 2011;41:82-4.
114. Khan MY, Mah MW, Memish ZA. Brucellosis in pregnant women. Clin Infect Dis 2001;32:1172-7.
115. Warner TT, Khoo SH, Wilkins EG. Reactivation of tuberculous lymphadenitis during pregnancy. J Infect 1992;24:181-4.
116. Eggermont E, Logghe N, Van De Casseye W, Casteels-Van Daele M, Jaeken J, Cosemans J, et al. Haemorrhagic disease of the newborn in the offspring of rifampicin and isoniazid treated mothers. Acta Paediatr Belg 1976;29:87-90.
117. Schaefer G, Zervoudakis IA, Fuchs FF, David S. Pregnancy and pulmonary tuberculosis. Obstet Gynecol 1975;46: 706-15.
118. Wilson EA, Thelin TJ, Dilts PV Jr. Tuberculosis complicated by pregnancy. Am J Obstet Gynecol 1973;115:526-9.
119. Bhargava P, Kuldeep CM, Mathur NK. Antileprosy drugs, pregnancy and fetal outcome. Int J Lepr Other Mycobact Dis 1996;64:457-8.
120. Snider DE Jr, Layde PM, Johnson MW, Lyle MA. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis 1980; 122:65-79.
121. Steen JS, Stainton-Ellis DM. Rifampicin in pregnancy. Lancet 1977;2:604-5.
122. Rocker I. Rifampicin in early pregnancy. Lancet 1977;2:48.
123. Ravid R, Toaff R. On the possible teratogenicity of antibiotic drugs administered during pregnancy- A prospective study. Adv Exp Med Biol 1972;27:505-10.
124. Buongiorno R, Schiraldi O. Treatment of typhoid fever in pregnancy. Chemioterapia 1984;3:136-9.
125. Cunningham FG, Morris GB, Mickal A. Acute pyelonephritis of pregnancy: A clinical review. Obstet Gynecol 1973;42: 112-7.
126. Hibbard L, Thrupp L, Summeril S, Smale M, Adams R. Treatment of pyelonephritis in pregnancy. Trans Pac Coast Obstet Gynecol Soc 1966;34:27-33.
127. Ross S, Burke FG, Sites J, Rice EC, Washington JA. Placental transmission of chloramphenicol (chloromycetin). J Am Med Assoc 1950;142:1361.
128. Scott WC, Warner RF. Placental transfer of chloramphenicol (chloromycetin). J Am Med Assoc 1950;142:1331-2.
129. Laiprasert J, Klein K, Mueller BA, Pearlman MD. Transplacental passage of vancomycin in noninfected term pregnant women. Obstet Gynecol 2007;109:1105-10.
130. Reyes MP, Ostrea EM Jr, Cabinian AE, Schmitt C, Rintelmann W. Vancomycin during pregnancy: does it cause hearing loss or nephrotoxicity in the infant? Am J Obstet Gynecol 1989;161:977-81.
131. MacCulloch D. Vancomycin in pregnancy. N Z Med J 1981; 93:93-4.
132. Saltzman DH, Eron LJ, Tuomala RE, Protomastro LJ, Sites JG. Single-dose antibiotic prophylaxis in high-risk patients undergoing cesarean section. A comparative trial. J Reprod Med 1986;31: 709-12.
133. Bourget P, Fernandez H, Delouis C, Ribou F. Transplacental passage of vancomycin during the second trimester of pregnancy. Obstet Gynecol 1991;78:908-11.
134. Bonacorsi S, Doit C, Aujard Y, Blot P, Bingen E. Successful antepartum treatment of listeriosis with vancomycin plus netilmicin. Clin Infect Dis 1993;17:139-40.
135. Schluter G. Ciprofloxacin: Toxicologic evaluation of additional safety data. Am J Med 1989;87:37S-9S.
136. Kubin R. Safety and efficacy of ciprofloxacin in paediatric patients-review. Infection 1993;21:413-21.
137. Wenk RE, Gebhardt FC, Bhagavan BS, Lustgarten JA, McCarthy EF. Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline. J Reprod Med 1981;26:135-41.
138. Allen WM. The use of progestational agents in pregnancy. Rocky Mt Med J 1965;62:31-5.
139. Genot MT, Golan HP, Porter PJ, Kass EH. Effect of administration of tetracycline in pregnancy on the primary dentition of the offspring. J Oral Med 1970;25:75-9.
140. Porter PJ, Sweeney EA, Golan H, Kass EH. Controlled study of the effect of prenatal tetracycline on primary dentition. Antimicrob Agents Chemother (Bethesda) 1965;5:668-71.
141. Ghannane H, Laghmari M, Aniba K, Lmejjati M, Benali SA. Diagnostic and management of pediatric brain stem abscess, a case-based update. Childs Nerv Syst 2011;27:1053-62.
142. Wang W, Guan P, Xu W, Zhou B. Risk factors for oral clefts: A population-based case-control study in Shenyang, China. Paediatr Perinat Epidemiol 2009;23:310-20.
143. Czeizel AE, Puhó EH, Acs N, Bánhidy F. High fever-related maternal diseases as possible causes of multiple congenital abnormalities: A population-based case-control study. Birth Defects Res A Clin Mol Teratol 2007;79:544-51.
144. Botto LD, Lynberg MC, Erickson JD. Congenital heart defects, maternal febrile illness, and multivitamin use: A population-based study. Epidemiology 2001;12:485-90.
145. Parker SE, Mai CT, Canfield MA, Rickard R, Wang Y, Meyer RE, et al. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res A Clin Mol Teratol 2010;88: 1008-16.
146. Antimicrobial resistance: issues and options. Washington, DC: Institute of Medicine; 1998.
147. Genisca AE, Frías JL, Broussard CS, Honein MA, Lammer EJ, Moore CA, et al. Orofacial clefts in the National Birth Defects Prevention Study, 1997-2004. Am J Med Genet A 2009; 149A:1149-58.
148. Andrade SE, Davis RL, Cheetham TC, Cooper WO, Li DK, Amini T, et al. Medication Exposure in Pregnancy Risk Evaluation Program. Matern Child Health J 2012;16:1349-54.
149. Law R, Bozzo P, Koren G, Einarson A. FDA pregnancy risk categories and the CPS: do they help or are they a hindrance? Can Fam Physician 2010;56:239-41.
150. Doering PL, Boothby LA, Cheok M. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks? Am J Obstet Gynecol 2002;187: 333-9.